Search

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

The use of toxin in paediatric strabismus

Strabismus is a common condition that affects up to 5% children and can be associated with abnormal visual development, double vision, loss of depth perception and impaired binocularity [1]. It can also cause cosmetic concerns, negatively impact psychosocial wellbeing and...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Sickle cell eye disease: an overview of vitreoretinal complications and their surgical management

Sickle cell disease is the most common genetic disorder worldwide and is associated with lifelong anaemia, intermittent pain and multi-organ morbidity. Ocular involvement can be associated with significant visual impairment due to the complications of proliferative sickle retinopathy (PSR). Occasionally...

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...

Blind Veterans UK calls on eye health professionals to direct blind and vision impaired veterans to vital support

A national charity is asking ophthalmologists and eye health professionals to help them reach out to the tens of thousands of blind and vision impaired ex-service men and women who are currently missing out on vital support to help them...

A pituitary tumour from 1927

The author shares a clinical case from Edinburgh Royal Infirmary’s archives. It is not often in the course of a clinical career that one gets the opportunity to review a patient who had been treated by a pioneer neurosurgeon some...